MARKET REPORT

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

BioPortfolio
Life Science Healthcare and Pharmaceutical Market Research and Corporate Data

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.
We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

Summary

RSV is a common cause of pediatric respiratory infections, and virtually all children will have been infected by the virus by the age of two years. Also, RSV is recognized as an important cause of respiratory illness in adults. The majority of RSV infections present as mild upper respiratory illnesses that often self-resolve within two weeks, although about 1% of cases develop serious lower respiratory complications requiring hospitalization. In older adults, RSV can result in significant morbidity and mortality, and is easily transmissible in living facilities, such as nursing homes. Children under the age of two years and adults over 64 years of age, with certain health conditions, are most at risk for severe RSV infections, and it is therefore recommended that they receive prophylactic treatment.

In each of the 7MM, GlobalData epidemiologists determined that the prophylactic RSV population in 2014, which includes the preterm infant (less than 37 weeks gestational age) population that survived to 2 years of age, the population of infants with neonatal chronic lung disease (CLD), the population of children with congenital respiratory or neuromuscular diseases that compromise respiratory function, the population of children with hemodynamically significant congenital heart disease, and the population of third-trimester pregnant women, was highest for the US, followed by the 5EU (France, Germany, Italy, Spain, and UK) and Japan. This trend was also seen in the hospitalized RSV population, where the US had the highest number of confirmed and estimated RSV hospitalized cases in 2014, followed by the 5EU and Japan.

GlobalData epidemiologists provide a well-rounded, evidence-based historical trend analysis and population forecast for the RSV prophylactic and hospitalized populations. This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment. Each population, including the hospitalized population, was also segmented by ages (0 years, 1 year, and 2 years) and by sex, thereby providing a granular visualization of the RSV prophylactic and hospitalized market in the 7MM. Furthermore, the forecast is based on an in-depth analysis of a comprehensive set of factors that may impact the RSV prophylactic and hospitalized populations. These factors include trends in population changes, births, preterm births, infant mortality, and the disease incidence, prevalence, and mortality.

Scope

- The Respiratory Syncytial Virus (RSV) Infection EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the for the pediatric population hospitalized due to RSV infection (hospitalized population), in addition to the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population) in these markets.

- The RSV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The RSV EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global RSV market.

- Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RSV prophylactics and therapeutics in each of the markets covered.

Additional Details

Publisher : Global Data
Reference : GDHCER111-15
Number of Pages : 69
Report Format : PDF
Publisher Information :

Table Of Contents for EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

List Of Tables in EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

1.1 List of Tables

List Of Figures, Charts and Diagrams in EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

1.2 List of Figures

How to Buy...

EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

https://www.bioportfolio.co.uk/product/17996

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.comWe will send you a Proforma Invoice and deliver your report on settlement.

Your Name: .....

Job Title: .....

Your Email: .....

Your Contact Phone: .....

Company Name: .....

Address: .....

.....

Post/Zip Code: .....

Country: .....

P.O. Number: .....

Any Other Instructions: .....

.....

Pricing Options: (please tick one)

○ **$3396** | Single User Price
○ **$6792** | Site License Price
○ **$10187** | Enterprise License Price

Payment Options: (please tick one)

○ **Online Credit Card** (we will email you the invoice with a payment link)
○ **Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature: .....

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.